期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
卷 6, 期 3, 页码 738-748出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jaip.2018.02.006
关键词
Severe asthma; Adolescent; Phenotype; Biologics; Difficult-to-treat asthma; Adherence; Psychosocial
资金
- American Board of Pediatrics Pediatric Pulmonary Subboard
- Teva
- GlaxoSmithKline (GSK)
- Merck
- Regeneron
- Novartis/Regeneron
- Sanofi/Regeneron
- Aviragen
- GSK/Regeneron
- National Institutes of Health (NIH)
- NIH
- Astra Zeneca
- Roche
- Novartis
- GSK
Severe asthma is associated with significant morbidity and is a highly heterogeneous disorder. Severe asthma in adolescence has some unique elements compared with the features of severe asthma a medical provider would see in younger children or adults. A specific focus on psychological issues and adherence highlights some of the challenges in the management of asthma in adolescents. Treatment of adolescents with severe asthma now includes 3 approved biologic phenotype-directed therapies. Therapies available to adults may be beneficial to adolescents with severe asthma. Research into predictors of specific treatment response by phenotypes is ongoing. Optimal treatment strategies are not yet defined and warrant further investigation. (C) 2018 American Academy of Allergy, Asthma & Immunology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据